Class I and class II anti-hla antibodies after implantation of cryopreserved allograft material in pediatric patients  by Hawkins, John A. et al.
324
monary patches have also been extensively used in the
reconstruction of the pulmonary arteries, aortic arch,
and right ventricular outflow tract in children. Although
their application has become widespread, very little is
known about the immunogenicity of the implanted cryo-
preserved material or the role that immunologic “rejec-
tion” may play in the late functional results of cryopre-
served allograft material. Because of the widespread
use of cryopreserved allograft material, some awareness
of the immunologic consequences of allograft implan-
tation and the activation of anti-HLA antibodies has
recently surfaced.1-3 No information is yet available on
whether this antibody response causes late dysfunction
of the allograft material, although if late cardiac trans-
plantation is found necessary, persistent anti-HLA anti-
bodies may affect application of this therapy.
This study was undertaken as an extension of a previ-
ous preliminary study3 in which we found that cryopre-
C ryopreserved human allograft material has beenextensively used over the past decade to reconstruct
a variety of congenital cardiac defects. Although valved
allografts have been the most commonly used material,
cryopreserved allograft patches and monocusp pul-
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served valved allografts elicit an anti-HLA antibody
response. We4 previously found that this response is
maximal 3 months after implantation, persists for at
least 1 year, and involves class I HLA alloantibodies.
The current study expands this preliminary study by
prospectively examining both HLA class I and class II
antibodies formed in response to cryopreserved allo-
graft patch (nonvalved) material and pulmonary mono-
cusp patches, in addition to cryopreserved valved allo-
grafts used in the reconstruction of a variety of
congenital cardiac defects.
Patients and methods
Patients. We prospectively enrolled 24 patients in our
study who received cryopreserved allograft material for
reconstruction of congenital cardiac defects. Ages of the
patients ranged from 7 days to 17 years (median 8.1 months)
and weights ranged from 3.1 to 55 kg (median 7 kg).
Diagnoses and treatments are given in Table I. The types of
allografts inserted included valved pulmonic allografts in 11,
valved aortic allografts in 5, pulmonary artery patch (non-
valved) allograft in 6, and pulmonary artery monocusp patch
allograft in 2. Thirteen of the 24 patients receiving an allo-
graft had undergone a previous open cardiac operation, all
without previous allograft implantation.
Control patients included 11 patients undergoing open car-
diac repair of congenital heart defects that did not require
placement of any allograft material. These patients also had
not had any previous allograft material implanted. Their ages
ranged from 1 week to 13 years (median 22 months).
Diagnoses for these control patients included ventricular sep-
tal defect in 4 patients, atrial septal defect in 4 patients, total
anomalous pulmonary venous connection in 1, pulmonary
atresia with intact ventricular septum in 1, and aortic stenosis
in 1. Three of these patients had undergone previous cardiac
surgery, but none had previous allograft material implanted.
Study methods. The study protocol was approved by the
Institutional Review Board at Primary Children’s Medical
Center. Informed consent was obtained from the parents or
guardian of each patient before entrance into the study. Blood
was obtained for an HLA panel reactive antibody (PRA) at
the following times: just before the operation, approximately
1 month after implantation of the allograft material, and
approximately 3 months and 12 months after allograft
implantation. All patients in both the study and control groups
had blood products that had undergone both irradiation and
leukocyte filtering to remove allogeneic white blood cells that
could sensitize the patients.5 All blood products were irradi-
ated with 137Cs at 30 Gy and were filtered with Purecell
leukocyte reduction filters (Pall Biomedical Products Co,
East Hills, NY).
HLA-A, HLA-B, and HLA-C loci serotyping was per-
formed on all patients by means of the standard complement-
dependent cytotoxicity (CDC) test and in-house serologic
reagents.3 PRA was determined by means of the sensitive
anti-human kappa light-chain immunoglobulin cytotoxicity
(AHG-CDC) technique against a frozen T-lymphocyte panel
composed of 40 individuals of diverse HLA type and racial
background. PRA was expressed as the percentage of lym-
phocyte panel members against which the patient’s serum
reacts and thus against which the patient has HLA class I
antibody.
HLA-DR/DQ antibodies were evaluated by means of a pre-
viously reported flow cytometry techinique.6 This technique
uses affinity-purified, soluble HLA-DR antigens from 30 dif-
ferent cell lines that are coupled individually to uniform latex
beads and then pooled to create a panel that represents the
majority of serologically recognized HLA-DR/DQ alloanti-
gens (Flow-PRA II Beads; One Lambda, Canoga Park,
Calif). After incubation of the beads with 0.02 mL of the
patient’s serum, washing and staining with saturating
immunoglobulin G goat anti-human immunoglobulin G, the
percent fluorescent positive beads (class II percent PRA) was
calculated after analysis on a Becton Dickinson FACScan
flow cytometer (Becton Dickinson & Co, Franklin Lakes, NJ). 
Statistical analysis. Comparisons between continuous
data were made with unpaired t test or analysis of variance
and the Scheffé post hoc analysis. All data were expressed as
mean ± standard deviation.
Results
Results are shown in Table II. Control patients had
virtually no detectable levels of class I antibodies
before the operation or 1 or 3 months after the opera-
tion. Because of this, we elected not to measure anti-




Tetralogy of Fallot with pulmonary atresia 3
Tetralogy of Fallot with severe pulmonary stenosis 2
Aortic stenosis with pulmonary valve replacement 4
and concomitant Ross procedure
Pulmonary stenosis/insufficiency 2
Supravalvular pulmonary stenosis after 2
arterial switch procedure
Tetralogy of Fallot with absent pulmonary valve 1
Recurrent aortic arch obstruction 2
Branch pulmonary artery stenosis/distortion 2
with single ventricle
Corrected transposition with pulmonary stenosis 1
Treatment
RV-PA valved allograft conduit 11
Orthotopic pulmonary valve insertion 5
Pulmonary artery monocusp insertion in RVOT 2
Pulmonary patch angioplasty 4
Allograft patch aortoplasty 2
RV-PA, Right ventricular–pulmonary artery; RVOT, right ventricular outflow
tract.
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bodies in the control group at 12 months. HLA class I
antibodies increased significantly in study patients
from minimal levels before the operation to signifi-
cantly elevated levels by 1 month, maximal levels at 3
months, and persistently elevated levels at 1 year after
implantation. Class II antibodies were also markedly
elevated at 1 and 3 months after implantation. Class I
antibodies tended to be lower in the patch group than
the valved allograft group at the 1-month and 3-month
intervals after implantation, but these differences did
not reach statistical significance (Table II).
There were no differences in either class I or class II
PRAs in infants less than 1 year of age as compared
with children older than 1 year of age at any of the
study times. Additionally, there were no differences in
class I or class II PRAs for aortic allograft material as
compared with pulmonary allograft material at any
study time after the operation. The numbers of patients
with allograft material implanted on the systemic side
of the circulation (n = 2) were insufficient to compare
differences in PRA for allograft material implanted in
the systemic circulation as compared with material
implanted in the pulmonary circulation (n = 22). In
addition, in the 12 patients in whom there was infor-
mation on ABO typing for both the donor and recipient,
8 patient-allografts were ABO compatible and 4 were
not. The class I antibody levels (PRA) were not signif-
icantly different at 1 month for ABO compatibility ver-
sus incompatibility (69% ± 25% vs 80% ± 13%) or at
3 months (85% ± 23% vs 93% ± 6%, P > .05).
Discussion
Cryopreserved allograft material has become very
important in the definitive repair and palliation of a
variety of congenital cardiac defects. Cryopreservation
allows preservation of endothelial and valve architec-
ture and viability with presumed improved durability
and with the convenience of long-term storage.7
Unfortunately, better preservation of allograft and
endothelium viability may actually sustain immuno-
genicity and elicit a more vigorous immunologic reac-
tion from the recipient; this response can theoretically
contribute to accelerated degeneration of allograft
valves or patch material. Previous studies in human
beings have demonstrated the presence of both class I
and class II anti-HLA antibodies in patients after allo-
graft implantation with homovital, antibiotic-pre-
served, and cryopreserved valved allografts.2-4,8-11
This study demonstrates, in a prospective manner,
that all cryopreserved allograft material (valves, mono-
cusp patches, and nonvalved pulmonary allograft
patches) elicits a strong immunologic response with the
production of both class I and class II anti-HLA anti-
bodies. This response is characterized by a brisk
response within the first month, which persists up to 1
year (and maybe indefinitely) after implantation.
Unique to our study is that we included a control group
of children for comparison, removing the possibility
that induction of these anti-HLA antibodies could be
due to blood transfusion, cardiopulmonary bypass, or
cardiac surgery. Moreover, both control and study
patients underwent transfusion with blood products
that were both leukopore filtered and irradiated to
remove most leukocytes that may activate anti-HLA
antibodies.5 Although some have suggested a more
rapid deterioration of cryopreserved allografts in young
infants and with aortic allograft material,12 we did not
find any differences between these groups with respect
to class I or class II PRA levels.
Although this study demonstrates the induction of
Table II. Class I and class II alloantibody measurements in 24 patients after implantation of cryopreserved allograft
material 
Percent panel reactive HLA antibody ± standard deviation
Valved allografts (n = 16) Allograft patch (n = 8) Total group (n = 24) Control group (n = 11)
Time after 
allograft implant Class I Class II Class I Class II Class I Class II Class I Class II
Preop 2% ± 6% — 0.4 ± 1.1% — 1.5% ± 5% — 2% ± 1% —
31 ± 8 d 69% ± 35%* 54% ± 45% 44% ± 27%‡ 46% ± 39% 62% ± 35%* 49% ± 38% 3% ± 1% —
3.3 ± 0.6 mo 98% ± 3%*† 86% ± 4% 84% ± 23%* 58% ± 31% 92% ± 15%*II 70% ± 26 2% ± 1% —
1.2 ± 0.2 y 85% ± 18%* — 85% ± 22%§ — 85% ± 18%*† — — —
*P < .001 versus preoperative value.
†P = .003 versus 1 month.
‡P = .01 versus preoperative value.
§P = .02 versus preoperative value.
IIP < .001 versus 1 month.
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anti-HLA antibodies in all allograft recipients, the
question remains as to whether this represents a form of
“rejection” analogous to that seen in solid organ trans-
plantation. Implicit in any definition of rejection is not
only a humoral or cellular immunologic response, but
also some functional consequence of this immunologic
reaction in the graft. No patient in this series has
required reoperation to date and PRA has been elevat-
ed in all, so it is impossible to correlate the exact PRA
level with the need for late reoperation or late function-
al results in our current study. Thus with PRA levels
elevated in all all patients, the central question is what
role these antibodies play in long-term allograft valve
or patch function.
Antibody deposition and T-cell infiltrates have been
previously demonstrated in pediatric valved con-
duits.9,12 Experimentally, cryopreserved aortic allograft
patches (nonvalved) have been shown to contain adven-
titial inflammation and intimal thickening and infil-
trates unrelated to the cryopreservation technique in
both a rat13 and sheep model.14 Despite the fact that
cryopreservation does contribute to some cell death in
allografts,13,15,16 viable endothelium, fibroblasts, and
dendritic cells have been demonstrated in cryopre-
served allografts, some up to 9 years after the opera-
tion.7,15,16 The simple presence of an antigen protein on
the allograft is not sufficient to induce an immunologic
anti-HLA response; the induction of both humoral and
cellular immunity also requires the presence of a live
cell.17 This implies that the production of these class I
and class II antibodies requires that there be some live
cells in cryopreserved allografts; these allografts can be
considered “transplants” in the broad sense of the word.
The relative absence of cellular infiltrates and struc-
tural abnormalities in valves after heart transplanta-
tion18,19 implies that immunosuppression may help pre-
vent some of the early failures seen in cryopreserved
allografts implanted in infants and children. Experi-
mentally, this has been shown in the rat model, with
improvement in allograft valve survival resulting from
treatment with cyclosporine A (INN: ciclosporin).20
Clinically, immunosuppression has been suggested and
andecdotally tried in some children undergoing implan-
tation of a cryopreserved allograft valve.21 Despite these
experimental and theoretical advantages of immunosu-
pression for cryopreserved allografts, there remains no
hard evidence to date that routine immunosuppression
will alter the antibody response and improve late allo-
graft function in children.
Perhaps more important than the debate over the
importance of immunologic factors in late function of
cryopreserved allografts is the implications that these
anti-HLA antibodies have for future heart transplanta-
tion. Although most of these children would be antici-
pated to do well in the long term, some of them have
significant heart disease or undergo palliative proce-
dures that may be anticipated to require late transplan-
tation. These may include patients with single ventricle
physiology undergoing pulmonary artery reconstruc-
tion with allograft patches or children with hypoplastic
left heart syndrome undergoing stage I palliation with
a Norwood procedure. The presence of donor-specific
HLA class I antibodies (PRA) has been demonstrated
to increase the risk of acute or hyperacute cardiac allo-
graft rejection and decrease graft survival.22,23
Elevation of class II antibodies is also associated with
an increased chance of hyperacute rejection in other
areas of transplantation.24 In addition, elevation of
PRA routinely requires prospective crossmatching
before transplantation and will therefore decrease the
available donor pool and increase waiting time.
Although many may not be anticipated to need late car-
diac transplantation, replacement of valved conduits will
be very likely in the growing child. The presence of pre-
formed antibodies to HLA antigens may cause an accel-
erated degeneration of future implanted valved allografts
when conduits are replaced because of dysfunction or
growth factors. Our study and those of others have
demonstrated long-term persistence of these antibodies,
up to 15 years after implantation in some cases.2
This study has several limitations that make it diffi-
cult to determine whether cryopreserved allografts
undergo “rejection” similar to that seen in solid organ
transplantation. We have demonstrated a definite
humoral response in children receiving cryopreserved
allografts, but we do not have any histologic or func-
tional data to definitely make a diagnosis of “rejec-
tion.” Some believe that immunology is unimportant in
the long-term function of these cryopreserved allo-
grafts,18 but clearly the preponderance of evidence sug-
gests the presence of an immunologic reaction that can
be demonstrated histologically in some circum-
stances.2-4,7-12,14 It is also difficult to determine whether
the elevated HLA class I and class II antibodies seen in
this study are in response purely to HLA mismatches
between donor and recipient. We did not make any
attempt to match allograft material with the recipient
with respect to ABO compatibility, but this should not
have induced HLA antibodies since ABO incompatibil-
ities are not accompanied by production of HLA anti-
bodies. Some have suggested that ABO incompatibili-
ty elicits a stronger immunologic reaction with
cryopreserved allografts,25 although previous clinical
studies have suggested no functional difference in
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valved allografts when ABO compatibility is ig-
nored.26,27 As suggested by Smith and associates,2 the
only way this may be sorted out in the future is with
better preoperative HLA and ABO matching of patient
and allograft or perhaps the use of immunosuppression
after the implantation of allograft material. In addition,
follow-up in our study was relatively short, and we do
not know how long these antibodies will persist or how
they will actually affect later cardiac transplantation. It
is presumed that these antibodies will persist for a sig-
nificant period of time2 because they are all
immunoglobulin G HLA antibodies3,4; however, some
anti-HLA antibodies that develop in response to blood
transfusion in children can and do disappear over
time.28 Only longer follow-up, prospective controlled
studies, and better characterization of the humoral and
cellular response will allow us to determine the specif-
ic effect these antibodies have on cryopreserved allo-
grafts and how we might alter them.
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Discussion 
Dr David R. Clarke (Denver, Colo). I congratulate you on
a very thought-provoking study. Let me be the first to agree
with the proposed existence of an immune response to surgi-
cally implanted allografts in children. Because pediatric car-
diac surgeons have come to rely on allograft valves, conduits,
and tissues for surgical repair of numerous anomalies, a thor-
ough understanding of allograft immunology becomes very
important to optimize outcome. The remainder of my com-
ments will be directed primarily toward outcome.
You have admitted that the duration of follow-up is short.
What is the total follow-up (average and range) of these allo-
graft recipients?
Dr Shaddy. The average follow-up is about 21⁄2 years, with
a range of 3 months to 41⁄2 years.
Dr Clarke. Even in early follow-up in our clinical experi-
ence, tissue calcification and degeneration in both the left and
right ventricular outflow tracts often results in homograft
explantation, particularly in children who are 1 year of age or
younger at initial implantation. 
Acknowledging that there might be an anti-HLA antibody
impact on late allograft dysfunction, has early degeneration
or calcification occurred in your series? Even though you
mentioned that none of the implants have been explanted,
have you seen any evidence of early degeneration?
Dr Shaddy. Yes, we have seen a moderate amount of allo-
graft dysfunction, and some of the stimulus for this work was
the work that you had previously published on this problem
in smaller children. 
Dr Clarke. Is there any correlation between the PRA lev-
els and the occurrence of this early degeneration?
Dr Shaddy. That is a very good question. Initially we had
hoped to find a less brisk and a more varied response to these
valved allografts or nonvalved allografts. Since all of the
patients have such a strong response, and a very similar
response, we are unable to differentiate between those who
have early or late graft failure and those who do not. Some
patients do very well, even some who have a very significant
immune response, whereas others do not. As yet, we have not
been able to discern the difference. 
Dr Clarke. Have you been able to correlate any difference
in the PRA response relative to the age of the patient at
implantation?
Dr Shaddy. No, there has been no difference with regard to
age. The younger children and the older children all had a
very similar response that was present by 1 month and broad-
ened in reactivity by 3 months.
Dr Clarke. In your study, 22 children had reconstruction of
the right ventricular outflow tract and 2 had tissue implanted
in the systemic circulation. Was there any difference in the
response between those two locations? Did you note any dif-
ference between aortic and pulmonary allograft tissue when
used in right ventricular outflow tract reconstructions?
Dr Shaddy. We have not been able to discern any differ-
ence between those groups.
Dr Clarke. In our series, as an alternative to immunosup-
pression, we have adopted a protocol to use anti-inflammato-
ry treatment for the first 6 weeks after implantation of allo-
grafts. Have you used a similar protocol or have you noticed
any difference in patients who were possibly treated for post-
pericardiotomy syndrome in terms of their development of
PRA response?
Dr Shaddy. No, we have not. 
Dr Clarke. In addition to the concern regarding the effect
of these antibodies on long-term allograft function, the ques-
tion is raised in your study about how this immunologic
response might affect subsequent reaction to cardiac trans-
plantation. We have an experience, although minimal, that
may support this concern. Five children in our series have had
allografts implanted and subsequently have undergone car-
diac transplantation. In 2 of them the PRA levels were not
known; one of these 2 patients is doing fine, and the other
died of chronic rejection. The other 3 patients are very inter-
esting. One of the children had a pretransplantation PRA of
only 5% but died very shortly after his transplant operation,
and we could not rule out hyperacute rejection. Another
patient had a transplant 61⁄2 years after allograft insertion.
Initially he had a PRA of 90%, but this dropped to 29% while
he was on the waiting list; however, liver and kidney failure
developed during that time, and he subsequently died 6
months after his cardiac transplantation, presumably of chron-
ic rejection as well. A final child was pretreated with intra-
venous immunoglobulin and azathioprine, and this resulted in
a drop in the PRA level from 96% to 12% at the time of car-
diac transplantation 71⁄2 years after his allograft implantation.
That child is presently alive and doing very well. 
Have you had similar experience with cardiac transplanta-
tion after allograft insertion? 
Dr Shaddy. Anecdotally, we have. One of the other moti-
vations for us to perform this study was the observation that 2
of our patients who had aortic reconstruction in the newborn
period and subsequently required transplantation, both over a
year after this initial procedure, had elevations in their PRA
level. One of those patients had a positive crossmatch. This
patient unfortunately died of unrelenting rejection after trans-
plantation. Our experience may be similar to yours, although
smaller, and this is part of the reason that we proceeded with
the study. We are concerned that these preformed antibodies
may become a problem in the small but significant number of
patients who will subsequently require transplantation.
Dr Clarke. Perhaps in contrast we have evaluated our
series of re-replacement of allografts with a second allograft.
We looked at this in 35 children with an average follow-up of
about 4 years and an overall follow-up of close to 8 years in
the longest case. Event-free analysis of primary versus reop-
erative recipients shows that, at 7 years, 77% of reoperated
survivors versus 69% of first-time allograft recipients are free
from allograft replacement. Thus they are not statistically dif-
ferent. The similarity implies that this immunologic response
may not affect reaction to subsequent allograft implants,
although admittedly the follow-up is short. Do you have any
experience that is similar?
Dr Shaddy. No, we do not have any experience with ana-
lyzing these patients, but that may be related to the short peri-
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od of follow-up in the current study. We have studied a few
patients whose allograft implantation was done many years
earlier, and we believe that the PRAs in some of these
patients are going to decrease significantly over time.
Perhaps they lose their immunoreactivity over time because
there is not an ongoing stimulus. This may go along with
pathologic findings that other investigators have reported,
showing that, when removed, these grafts do not have inflam-
matory cells in them and do not appear to be undergoing
rejection at that time. The reason may be that the rejection
process has already been completed and the immunologic
response then would have disappeared. Thus these patients
may not be at risk for subsequent graft failure with reimplan-
tation. That is only speculation.
Dr Vaughn A. Starnes (Los Angeles, Calif). Dr Shaddy, I
have two comments and one question. The whole idea of
immunologic reactivity has plagued transplantation for 25
years. There is no corelation between the immunoreactivity
of our patients and transplantation. Many of these patients
have highly reactive antibodies to the graft and have no T
cell–mediated response. What you are seeing is a B
cell–mediated response. I would caution people to take this
information in context, because what we are interested in
knowing is whether this is really a marker for ongoing or pos-
sible histologic damage in the future. The histologic damage
would probably be a T cell–mediated response, not a B
cell–mediated response. Therefore, although it is very inter-
esting and worrisome, I would be more concerned about
whether the patient needed future transplantation. We too
have had the experience of performing transplantation in 4
patients who had had allografts in the neonatal period. We
initially gave them immunoglobulin and were able to get the
PRA down to about 5% to 10% before performing successful
transplantation. That is what we do routinely now for those
individuals who encounter this problem. That is a helpful
adjunct to performing transplantation in patients with
immunoreactive PRA panels. 
Dr Edward Verrier (Seattle, Wash). This is a phenomenon
that exists both in children and in adults. The problem is
plaguing the Ross operation right now. In our series of about
100 patients, 3 patients have had to have their pulmonary
autograft explanted and a new one implanted because of what
appears to be a very strong inflammatory response in the con-
duit. Others who have performed the Ross operation have had
similar small percentages of patients. 
My first question is this: If you had access to the tissue,
what would you look for to discern some of the issues relat-
ed to what Vaughn stated and to prospectively then determine
whether it is possible to predict which patients are going to
get this response?
Second, if we could determine which patients will have
that response, would it be worthwhile even within The
Western Thoracic Surgical Association, where we have a
number of resources, to conduct a multi-institutional study in
which we would get access either to the preformed panels
beforehand or to tissue and then be able to look at it in a more
systematic fashion? This problem has a big impact not only
on the tissue that we use in children but also increasingly in
adults.
Dr Shaddy. Are you referring to explanted tissue?
Dr Verrier. Yes. If you remove the right ventricular–pul-
monary artery homograft to implant another homograft, you
have access to that tissue. We are looking at such tissue
experimentally right now with a group of immunologists at
the University of Washington in an attempt to discern any-
thing unique about that histologic inflammatory response that
would help us learn how to treat it. We still would not neces-
sarily be able to predict who will have the response, because
only a relatively small percentage of patients actually lose the
allograft. However, on the basis of your data, there is an
ongoing immunologic phenomenon that we need to further
elucidate.
Dr Shaddy. As a nonimmunologist, I would first look for
evidence of cellular infiltration, as we would do in a piece of
a biopsy specimen from the heart. Also, we would look at B
cell–mediated responses, including immunoglobulin, com-
plement, and evidence of immune reaction in the vasculature
and in the microvasculature on the grafts. We have not had an
opportunity to do that. Others have looked at these grafts
longer and claim there is no inflammatory response, so I sus-
pect we would need to look for evidence of inflammatory or
antibody-mediated responses as well. An even more intrigu-
ing approach would be to take some of the allograft that is
being implanted and to somehow preserve, grow, or immor-
talize those cells. It may then be possible to look at the inter-
action of the allograft tissue and the patient’s serum over time
to see which patient is reacting against that piece of allograft
that is now implanted in the patient. It might then be possible
to predict who is going to have allograft dysfunction and an
immunologic response and who may not.
